Video Series

Barriers inhibiting optimal CKD treatment for patients are underlined.

Ghassan Abou-Alfa, MD, MBA, and Mohamed Salem, MD, provide insights regarding potential clinical pathway-driven challenges associated with HCC management.

A panel of medical experts open a discussion surrounding key treatment strategies in management of hepatocellular carcinoma (HCC).

Medical experts explore the main treatment goals and modalities beyond pharmacotherapies for mCRC treatment, and discuss targetable mutations being explored in mCRC.

Joseph M. Coney MD, FACS, discusses health equity considerations for patients with diabetic macular edema and the critical role a timely diagnosis and sufficient health literacy plays in effective therapy.

In his final thoughts, Dr Gerds discusses emerging therapies for the treatment of PV.

Uncontrolled PV is highlighted by a key opinion leader.

Treatment of DLBCL amid comorbidities in elderly patients is highlighted.

Dr Gordon discusses use of bispecifics for management of patients with relapsing DLBCL.

Experts review their considerations when adding immunotherapy to both surgical patients and radiation patients with NSCLC.

Experts discuss the current standard treatment options for patients diagnosed with early-stage NSCLC [non-small cell lung cancer].

A conversation on patient tolerance of CTLA-4 immunotherapies, alongside an exploration of treatment-related adverse reactions is discussed by a panel of experts.

John Anderson, MD, discusses the management of quality care for patients with CKD.

Ken Cohen, MD, illustrates payer programs designed to support patient care in CKD treatment.

Closing thoughts from all panel members.

A conversation on the pros and cons of telehealth in acne treatment.

Dr Gerds explores the pros and cons of the present treatment approach for PV.

Panelists highlight challenges facing both patients and caregivers associated with colorectal cancer treatment.

Dr Gordon provides strategies for navigating treatment-associated toxicities in DLBCL management as directed by NCCN Guidelines.

Dr Gerds provides insight regarding the evaluation of dosing and effectiveness in PV treatment.

A medical expert examines first6, second-, and third-line systemic therapies for DLBCL in accordance with NCCN Guidelines.

Experts explore the importance of early detection of metastatic colorectal cancer.

Specialists examine techniques for assessing pathological complete responses and various methods for response measurement in patients with NSCLC.

Experts explore strategies to increase the number of patients benefiting from multidisciplinary team (MDT) collaboration and the factors MDTs consider when deciding between surgical resection and nonsurgical options for early-stage NSCLC.

Specialists address the intricate factors between comorbidities, efficacy, and tolerance, which influence their treatment approaches at the time of diagnosis.

Specialists evaluate their clinical strategies for managing second-line driver-negative and initial PD-L1 negative patients.

Medical experts discuss considerations for ESRD during CKD treatment as well as updated guidelines for treatment of chronic kidney disease.

Jennifer Green, MD, provides considerations for the use of SGLT2 inhibitors in treatment of CKD.